Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles

B. King, Becka Hughes, S. Navarro-marchal, V.g. Brunton, E. Poradosu, Neil O. Carragher, A. Unciti-broceta

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)S113
JournalEuropean Journal of Cancer
Publication statusPublished - 1 Oct 2022

Cite this